文献速递类风湿关节炎

Upadacitinib与阿达木单抗在TNFi治疗失败后类风湿关节炎患者中的12周结果:SELECT-SWITCH研究

Upadacitinib vs adalimumab in patients with rheumatoid arthritis and a prior inadequate response or intolerance to a tumour necrosis factor inhibitor: 12-week results from the randomised, double-blind, SELECT-SWITCH study.
PubMed 文献 · Ann Rheum Dis · 2026-04-15

SELECT-SWITCH随机双盲试验比较了Upadacitinib与阿达木单抗在第一种TNFi治疗失败后的活动性RA患者中的疗效。12周时Upadacitinib组达到DAS28-CRP≤3.2的比例显著高于阿达木单抗组,主要终点达成,安全性相似。

要点

  • 第一种TNFi失败后换用Upadacitinib比换用阿达木单抗更多患者达到DAS28-CRP≤3.2。
  • Upadacitinib在ACR50、DAS28-CRP<2.6、DAS28-CRP变化和疼痛改善上均优于阿达木单抗。
  • HAQ-DI变化两组无显著差异,安全性相似。

核心结论

  • 在第一种TNFi治疗失败后的活动性RA患者中,Upadacitinib在12周时达到DAS28-CRP≤3.2的优效性优于阿达木单抗。

研究设计与样本

  • 随机、双盲、1:1对照试验,纳入对一种非阿达木单抗TNFi应答不足或不耐受且接受稳定甲氨蝶呤的活动性RA患者492例。
  • 干预为Upadacitinib 15 mg每日一次或阿达木单抗40 mg每两周一次。

关键数值与推荐

  • 主要终点为12周DAS28-CRP≤3.2的优效性。
  • 排序次要终点包括ACR50、DAS28-CRP<2.6、DAS28-CRP变化、疼痛变化和HAQ-DI变化。

临床怎么用

  • 对于第一种TNFi治疗失败的活动性RA患者,换用Upadacitinib可能比换用第二种TNFi(阿达木单抗)获得更高的12周疾病活动度控制率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: After the first tumour necrosis factor inhibitor (TNFi) failure, patients with rheumatoid arthritis (RA) often cycle to a second; however, switching mechanisms of action has been postulated to improve outcomes. The ongoing SELECT-SWITCH trial compared upadacitinib with adalimumab for active RA after first TNFi failure at 12 weeks. METHODS: Patients with inadequate response or intolerance to 1 nonadalimumab TNFi receiving stable methotrexate were randomised (1:1) to 15 mg once daily upadacitinib or 40 mg every-other-weekly adalimumab. The primary endpoint was achieving superiority in Disease Activity Score 28 (DAS28)-C-reactive protein (CRP) ≤3.2 at week 12. Ranked secondary endpoints (week 12, superiority) were (1) achieving ≥50% improvement in American College of Rheumatology response criteria (ACR50); (2) achieving DAS28-CRP <2.6; change from baseline in (3) DAS28-CRP; (4) pain; (5) Health Assessment Questionnaire Disability Index (HAQ-DI). RESULTS: Overall, 492 patients were randomised. Baseline characteristics were balanced between groups. Week 12 DAS28-CRP ≤3.2 response was superior with upadacitinib (43.3%) vs adalimumab (22.4%; difference, 21.0% [95% CI: 12.9-29.1]; P < .0001) as were ACR50 (38.2% vs 26.8% [P = .0068]), DAS28-CRP <2.6 (28.4% vs 14.5%; P = .0002), mean changes in DAS28-CRP (-2.432 vs -1.840; P < .0001) and pain (-3.165 vs -2.373; P = .0005), but not in HAQ-DI (-0.523 vs -0.496; P = .5849). Safety was comparable between treatments. CONCLUSIONS: The primary endpoint of the SELECT-SWITCH trial was met, with a higher percentage of patients with active RA who switched to upadacitinib after first TNFi failure achieving DAS28-CRP ≤3.2 at 12 weeks than those cycling to a second TNFi, adalimumab, with generally similar safety profiles. GOV IDENTIFIER: NCT05814627.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Mysler E, Sidiropoulos PI, Balanescu A, et al. Upadacitinib vs adalimumab in patients with rheumatoid arthritis and a prior inadequate response or intolerance to a tumour necrosis factor inhibitor: 12-week results from the randomised, double-blind, SELECT-SWITCH study. Ann Rheum Dis. 2026. PMID: 41991443. doi:10.1016/j.ard.2026.03.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。